ASCO 2019: Olaparib Finds a Place to Treat Prostate Cancer
DNA repair mechanism damage targeted in advanced disease CHICAGO — Patients diagnosed with...
Read More
Meeting Coverage
ASCO 2019: Men and Women Doctors Report Sexual Harassment
New survey highlights suspected financial impact CHICAGO – Gynecologic oncologists report that...
Read More
ASCO 2019: FDA Launches Project Facilitate to Ease Access to Novel Agents
But the FDA wants to know outcomes for patients taking unapproved drugs CHICAGO — The FDA says it...
Read More
ASCO 2019: New Agent Targets Metastatic Bladder Cancer
Metastatic disease responds to enfortumab vedotin CHICAGO – A new agent that acts as a smart bomb...
Read More
ASCO 2019: Laparoscopy for Liver Mets Equals Open Surgery
Colon cancer spread excised in minimally invasive procedure CHICAGO – In cases where colon cancer...
Read More
ASCO 2019: PARP-Inhibitor Achieves ‘Complete Response’ in Pancreatic Cancer
BRCA was the key to success CHICAGO — Pancreatic cancer trials don’t report complete responses,...
Read More
ASCO 2019: Studies Offer Evidence—ACA Improves Care
Too little, too late to save Obamacare? CHICAGO — As the nation prepares to once again litigate...
Read MoreASCO 2019: Multiple Myeloma Survival Linked to Income and Insurance
Zip code can be a risk factor CHICAGO – Multiple myeloma is a serious and often deadly disease, but outcomes may be better for those whose medical care is covered by private insurers. Or, it’s possible all survival, like...
Read More
ASCO 2019: ENZAMET and TITAN Are Wins in Prostate Cancer
Survival is about more than testosterone suppression CHICAGO — Men with metastatic hormone...
Read More
ASCO 2019: Metformin No Help in Advanced Prostate Cancer
Diabetes drug offers no benefit to non-diabetic patients CHICAGO – Metformin, when added to...
Read More
ASCO 2019: Ribociclib Claims First Ever Overall Survival Benefit for Targeted Therapy. MONALEESA 7 confirms CDK4/6 inhibitor efficacy in younger women
By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Adding the CDK4/6 inhibitor ribociclib to...
Read More
ASCO 2019: Getting on the Same Page with mCODE. ASCO unveils initiative to topple EHR ‘Tower of Babel’
CHICAGO — What if all health systems, all hospitals, and all oncologists spoke the same language —...
Read More
ASCO 2019: Pembrolizumab Changes ‘the Conversation’ in GI Cancer
Immunotherapy drug works as well as chemotherapy in advanced patients CHICAGO – In a...
Read More
Conference Highlights: DDW 2019
New research was presented at DDW 2019, the annual Digestive Disease Week, from May 18-21 in San...
Read More
Conference Highlights: ATS 2019
New research was presented at ATS 2019, The annual American Thoracic Society International...
Read More
ASCO 2019: Diet to Prevent Breast Cancer Death, Precision Medicine, and More
By Peggy Peck, Editor-in-Chief, BreakingMED In advance of the American Society of Clinical...
Read More
ASCO 2019: Pediatric Precision Medicine: First Find the Target. Studies Suggest Age Is No Barrier to Targeted Therapy
Pediatric cancers are killers that often elude approved therapies, but the advent of precision...
Read More
ASCO 2019: Determining Dose: It’s All About the Patient When the Patient Is Older and Frail, Consider Low Dose
Some cancers are more common in elderly — often frail— persons, and Peter S. Hall, PhD, a medical...
Read More
ASCO 2019: What to Expect When 32,000 Cancer Experts Arrive in the Windy City
By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO – What is the best way to treat hormone...
Read More
ASCO 2019: Can a Dietary Intervention Prevent Breast Cancer Deaths? A Long Look Back at the Women’s Health Initiative Offers an Answer
Following a cohort of postmenopausal women for almost 20 years has turned up what is being...
Read More